VERTEX PHARMACEUTICALS INC / MA (VRTX) Financials
Annual revenue, profitability and per-share results for VERTEX PHARMACEUTICALS INC / MA, as reported in SEC filings.
Revenue • FY2025
$12B
▲ 8.9%YoY
Net income • FY2025
$3.95B
▲ 838.1%YoY
Gross margin • FY2025
86.2%
Diluted EPS • FY2025
$15.32
▲ 836.5%YoY
Annual income statement
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $12B | $3.95B | $10.35B | $15.32 | $3.19B | 34.8% | +8.9% |
| FY2024 | $11.02B | -$535.6M | $9.49B | $-2.08 | -$790.3M | -2.1% | +11.7% |
| FY2023 | $9.87B | $3.62B | $8.61B | $13.89 | $3.34B | 38.8% | +10.5% |
| FY2022 | $8.93B | $3.32B | $7.85B | $12.82 | $3.93B | 48.2% | +17.9% |
Figures as reported in VERTEX PHARMACEUTICALS INC / MA's 10-K filings on SEC EDGAR. Fiscal years may differ from calendar years.
Financials for companies related to VRTX
Never miss a VRTX filing.
Get an email when VRTX files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Source: SEC EDGAR.